Neutralizing antibodies against KP.2 and KP.3: why the current vaccine needs an update-Reference-Cited by-同舟云学术

Neutralizing antibodies against KP.2 and KP.3: why the current vaccine needs an update

Published:2024-08-16 Issue: Volume: Page:
ISSN:1434-6621
Container-title:Clinical Chemistry and Laboratory Medicine (CCLM)
language:en
Short-container-title:

Author:

Gillot Constant¹,David Clara²,Dogné Jean-Michel¹,Cabo Julien³^ORCID,Douxfils Jonathan¹²⁴^ORCID,Favresse Julien¹³

Affiliation:

1. Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center , University of Namur , Namur , Belgium

2. Research and Development Department , Qualiblood s.a. , Namur , Belgium

3. Department of Laboratory Medicine , Clinique St-Luc Bouge , Namur , Belgium

4. Department of Biological Hematology , Centre Hospitalier Universitaire Clermont-Ferrand, Hôpital Estaing , Clermont-Ferrand , France

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/cclm-2024-0919/pdf

Reference21 articles.

1. Kaku, Y, Uriu, K, Kosugi, Y, Okumura, K, Yamasoba, D, Uwamino, Y, et al.. Virological characteristics of the SARS-CoV-2 KP.2 variant. Lancet Infect Dis 2024;24:e416. https://doi.org/10.1016/s1473-3099(24)00298-6.

2. Ren, W, Ju, X, Gong, M, Lan, J, Yu, Y, Long, Q, et al.. Characterization of SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by cell entry and immune evasion. mBio 2022;13:e00099–22. https://doi.org/10.1128/mbio.00099-22.

3. Nelson, G, Buzko, O, Spilman, P, Niazi, K, Rabizadeh, S, Soon-Shiong, P. Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. bioRxiv 2021. 2021.01.13.426558.

4. Kumar, P, Jayan, J, Sharma, RK, Gaidhane, AM, Zahiruddin, QS, Rustagi, S, et al.. The emerging challenge of FLiRT variants: KP.1.1 and KP.2 in the global pandemic landscape. QJM: Int J Manag 2024;117:485–7. https://doi.org/10.1093/qjmed/hcae102.

5. WHO. SARS-CoV-2 variatns follow-up; 2024. Available from: https://www.who.int/fr/activities/tracking-SARS-CoV-2-variants.